Introduction. An antenatal corticosteroid (ACS) delivery interval of 24 h to seven days is commonly referred to as optimal timing. We aimed to investigate whether the ACS delivery interval was associated with the obstetric indication for treatment and with neonatal complications. Material and methods. The study was a retrospective chart review of clinical data from preterm neonates delivered at the Sk ane University Hospital, Lund University, Sweden, from 1 January 2013 to 31 December 2016. The ACS delivery intervals were compared between groups of women with various clinical scenarios and related to neonatal outcomes. Results. The study included 498 preterm neonates from 431 women. One to seven days before delivery, 41% of the women received ACS. Women with preterm prelabor rupture of membranes or vaginal bleeding had a median ACS delivery interval of 7.5 and eight days, respectively, compared with women with maternal/fetal indications or preterm labor (three and two days, respectively) (p < 0.001). Neonates with an ACS delivery interval of more than seven days were at a higher risk of respiratory distress syndrome [odds ratio (OR) 2.00, 95% confidence interval (CI) 1.05-3.79] and moderate or severe bronchopulmonary dysplasia (OR 2.78, 95% CI 1.45-5.33) than were neonates with an ACS delivery interval of one to seven days. Conclusion. Optimal timing of ACS treatment varied significantly based on the clinical indication. Women with preterm prelabor rupture of membranes or vaginal bleeding were more likely to have an ACS delivery interval of more than seven days. A prolonged ACS delivery interval was associated with an increased risk of neonatal respiratory morbidity and a prolonged stay in the neonatal care unit, but not with neonatal mortality.
Introduction
Administration of antenatal corticosteroids (ACS) to women at risk for preterm delivery is one of the most effective treatments for reducing neonatal morbidity and mortality. Since Liggins and Howie first suggested risk reduction following antenatal steroid administration (1) , numerous studies have confirmed that treatment with
Key message
A prolonged antenatal corticosteroids delivery interval is associated with an increased risk of neonatal morbidity. Knowledge of how the timing of steroids differs between clinical scenarios could help physicians to optimize administration of antenatal corticosteroids. ACS reduces the risk of respiratory distress syndrome, intraventricular hemorrhage, necrotizing enterocolitis and neonatal death in preterm infants (2) (3) (4) . Treatment with ACS is therefore recommended for all women at risk for preterm birth prior to 34 weeks of gestation (5) .
The number of days between ACS administration and delivery is of importance to achieve optimal benefit for the newborn. Several studies suggested that the steroid effect diminishes seven days after administration (4, (6) (7) (8) (9) . There is uncertainty as to how short the ACS delivery interval can be without reducing steroid efficacy. A recent observational study presented evidence that an ACS delivery interval of ≤12 h could be beneficial (4) .
The various pathways leading to preterm birth are complex and are not yet fully understood; consequently, suboptimal timing of ACS occurs in many cases due to the difficulty of predicting preterm birth (10) (11) (12) (13) . The ability to give optimally timed ACS treatment is dependent on the distinct clinical scenario preceding the preterm delivery (12) . In this study, an ACS delivery interval of >24 h and ≤7 days was defined as optimal timing.
The primary objective of this single-center study was to assess whether the timing of ACS was associated with the obstetric indication for treatment and with neonatal complications. The secondary objective was to investigate whether neonates with an optimal ACS delivery interval were less likely to suffer from neonatal complications compared with neonates treated with suboptimally timed ACS administration.
Material and methods
The study was a retrospective chart review of clinical data on preterm neonates delivered at the Department of Obstetrics at the Sk ane University Hospital, Malm€ o and Lund, Sweden, from 1 January 2013 to 31 December 2016, and admitted to the neonatal intensive care unit (NICU). Data was retrieved and analyzed during January-March, 2017. All preterm neonates with a gestational age between 23 +0/7 and 33 +6/7 weeks were included. Neonates born at external hospitals and then transferred to the NICU at Sk ane University Hospital in Lund were not included, as the antenatal medical records were not available for scrutiny.
The following obstetric characteristics were retrieved from obstetric charts: indication to initiate treatment with ACS (indication to treat), ACS delivery interval, gestational age at admission and whether intravenous antibiotics or tocolytics were administered. Baseline maternal characteristics were retrieved from antenatal care charts, including maternal age, smoking, body mass index, comorbidity, parity and history of previous preterm delivery. The indications to initiate treatment with ACS were classified in a hierarchical classification system as one of the following: preterm labor defined as regular uterine contractions causing cervical changes, preterm prelabor rupture of membranes (PPROM; more than one hour before the onset of labor), fetal indications (such as intrauterine growth restriction or placental insufficiency), maternal indications (such as severe preeclampsia or HELLP syndrome (hemolysis, elevated liver enzymes and low platelet count)), abnormal vaginal bleeding or asymptomatic changes of the cervix (cervical length <15 mm and/or dilation >4 cm).
Neonatal outcome data retrieved from the Swedish Neonatal Quality register included birthweight, mode of delivery, NICU admission in days, respiratory distress syndrome (RDS), moderate and severe bronchopulmonary dysplasia (BPD), necrotizing enterocolitis, 3 rd and 4 th degree intraventricular hemorrhage, retinopathy of prematurity stage ≥3, oxygen dependence at 28 days and at 36 gestational weeks, and neonatal mortality within 28 days. All neonatal outcome measures were collected during hospital stay and there was no follow up after discharge. Moderate to severe BPD was defined as oxygen dependency beyond 28 days and/or beyond the corresponding to 36 weeks' gestational age. The composite adverse neonatal outcome included at least one of the following: severe BPD, intraventricular hemorrhage grade 3 or 4, neonatal mortality, necrotizing enterocolitis and retinopathy of prematurity stage ≥3.
Women and their offspring were categorized according to the timing of ACS as one of the following: the first dose of ACS given less than 24 h before delivery, >24 h and ≤7 days before delivery and >7 days before delivery. In addition, a fourth category of no exposure to ACS was computed. If the woman received a rescue dose of ACS, the timing was categorized according to the rescue dose. Each woman was assigned to one category of indications and one category of timing by J.F. and K.K., and the medical records were reviewed and discussed in cases of disagreement.
According to the local protocol, women at risk of preterm delivery (from 23 +0/7 to 33 +6/7 gestational weeks) receive two intramuscular injections of 12 mg betamethasone 24 h apart. If the delivery is predicted to happen sooner than 24 h after the first dose, a shorter interval between the two doses is considered, which means that some of the women in the group with ACS delivery interval <24 h received two doses of betamethasone. A rescue dose of 12 mg betamethasone is considered when the gestational age is below 28 +0/7 and more than seven days have passed since the initial ACS course.
Differences between the groups were analyzed using Pearson's chi-squared analysis, the Mann-Whitney U-test, the one-way analysis of variance and the Kruskal-Wallis test as appropriate. Binary and log-linear regression models adjusted for confounders were used to analyze associations between the timing of ACS and the neonatal outcome. The regression models were adjusted for variables known to impact the neonatal outcome: gestational age at delivery, intrauterine growth restriction (neonatal weight <2 SD of the expected weight for gestational age), the indication to treat and treatment with rescue ACS, tocolytics or antibiotics. The results from the logistic regression models are presented as the odds ratio (OR) with a 95% confidence interval and the results from the log-linear (Poisson) regression models as the exponentiated regression coefficient (expB) with a 95% confidence interval. A two-sided p-value of <0.05 was considered statistically significant. SPSS STATISTICS 24.0 (SPSS Inc., Chicago, IL, USA) was used for all statistical analyses.
Ethical approval
The local ethics committee advised that no informed consent was deemed necessary for this study as data were being used for quality control and were collected as part of routine clinical care. 
Results
A cohort of 500 preterm neonates delivered at the Sk ane University Hospital during the study period and subsequently admitted to the NICU was identified in the database. Two neonates not receiving ACS due to poor prognosis (lethal malformations) were excluded. The remaining 498 neonates were delivered by 431 women, as 15.1% of the included neonates were from multifetal pregnancies (including one set of quadruplets and two sets of triplets).
Demographic, medical and obstetric characteristics are shown in Table 1 . The cesarean section rate for the entire cohort was 68.2%; this rate was higher in the subgroup of women delivered due to maternal and fetal indications (99% and 96%, respectively). The median gestational age at delivery was 28 +2/7 weeks with a median maternal admission to birth interval of four days (range 0-69) and a median ACS delivery interval of three days (range 0-53). Optimal treatment with ACS (>24 h and ≤7 days before delivery) was given to 40.8% of the included women. Twenty-two patients (5.1%) did not receive ACS (Table 2) . Rescue ACS was administered to 27 of the 72 women eligible according to local protocol; eight of these women had a rescue ACS delivery interval of >24 h and ≤7 days.
The timing of ACS varied between the indications to treat. Women with maternal indications to treat were the group most likely to have an ACS delivery interval of >24 h and ≤7 days (64.9%). For the other clinical indications, the corresponding percentages ranged from 25 to 39.8% (p < 0.001). Of the women receiving ACS after PPROM or vaginal bleeding, 50% had an ACS delivery interval of more than seven days, whereas for the other clinical indications the corresponding percentages ranged from 16.5 to 38.5% (p < 0.001) ( Table 2) .
Correspondingly, women with PPROM or vaginal bleeding had a longer ACS delivery interval when measured as a continuous variable (median of 7.5 and 8 days, respectively) compared with women with maternal/fetal indications or preterm labor (median two to three days) (p < 0.001) (Fig. 1) .
The cohort was stratified by gestational age (<28 weeks and ≥28 weeks) and analyzed for differences in ACS delivery interval for the total cohort and for each subgroup of clinical indications. The ACS delivery interval was not statistically different between preterm deliveries before and after 28 weeks (data not shown).
In the regression models, the optimally timed group (ACS delivery interval of >24 h and ≤7 days) was set as the reference group. The potential confounders gestational age at birth, indication to treat, small for gestational age or intrauterine growth restriction, and treatment with rescue ACS, tocolytics or antibiotics were included in the models. Neonates with an ACS delivery At admission to the antenatal care services. Missing data: BMI, n = 92; previous delivery <37 weeks, n = 11; delivery by cesarean section, n = 3; diabetes mellitus, n = 74; other major comorbidity, n = 74; smoking, n = 86.
interval of more than seven days were more likely to suffer from RDS [OR 2.00, 95% confidence interval (CI) 1.05-3.79] and from moderate or severe BPD (OR 2.78, 95% CI 1.45-5.33) compared with the reference group; there were no significant differences between these groups regarding the composite outcome or neonatal mortality. Neonates with an ACS delivery interval of <24 h were more likely to suffer from RDS compared with the reference group (OR 2.16, 95% CI 1.11-4.22) but there were no significant differences between these groups regarding the composite adverse outcome, neonatal mortality, or moderate or severe BPD (Table 3, Supporting Information Table S1 ).
According to the log-linear regression (Poisson) models, neonates with an ACS delivery interval of more than seven days had a longer stay in the NICU [exp(B) = 1.27, 95% CI 1.23-1.31] and a longer treatment with oxygen [exp(B) = 1.44, 95% CI 1.38-1.50] compared with neonates in the reference group. Neonates with an ACS delivery interval of <24 h did not have a statistically significant different oxygen treatment time, but they remained in the NICU for longer [exp(B) = 1.13, 95% CI 1.09-1.17] compared with the reference group (Table 3) .
Discussion
The timing of ACS influences the likelihood of benefit from treatment. In this study, optimal timing of ACS was achieved in 40.8% of the women, a rate comparable to others' (8, 12) . The timing of ACS varied greatly depending on the obstetric indication for treatment; women with PPROM or vaginal bleeding had a median ACS delivery interval of more than seven days, significantly longer than women treated for other indications.
The study confirmed previous findings of an increased rate of neonatal respiratory complications and an increased number of days in the NICU when the ACS delivery interval was more than seven days after adjusting for major confounders such as gestational age and the obstetric indication for treatment (4, 14) . Previous studies have adjusted for an incomplete set of obstetric indications, such as PPROM and preeclampsia (4, 8, 14, 15) . To our knowledge this is the first study adjusting for obstetric indications in a systematic way when analyzing the associations between the timing of ACS and the neonatal oucome.
The proportion of women with an ACS delivery interval exceeding seven days (29%) is most likely an underestimation, since the women treated with ACS and delivered beyond 34 weeks were not included. Further, Antenatal corticosteroids delivery interval (days) according to the obstetric indication groups. The boxplot presents the medians, quartiles, and the 5th and 95th percentiles. The one-way betweengroup analysis of variance showed a statistically significant difference between all groups except for the cervix group, p < 0.0001. PPROM, preterm prelabor rupture of membranes; PTL, preterm labor. *Asymptomatic changes of the cervix (shortening or dilation). the proportion of women with an ACS delivery interval <24 h (25%) could also be underestimated, since women delivered preterm at secondary regional hospitals due to emergency situations or rapid progression of labor were not included. This retrospective chart review study included a large single-center cohort with transparent inclusion and exclusion criteria. All patient records were meticulously scrutinized for the indication and timing of ACS treatment and no data was missing in the timing and indication variables. Efforts to limit influence from confounding factors were made by including gestational age at delivery, weight deviation at birth, indication to treat, and treatment with tocolytics and antibiotics in the regression analyses.
A large number of caregivers handling the medical charts and the quality register could bias the documentation. The data abstractors were not blinded to the study's objective, which might permit reviewer bias (16) . Furthermore, only inborn neonates were included, which might permit for selection bias. The background maternal characteristics were missing for a few women attending antenatal care outside our region and six neonates (1.2%) were not included in the regression analyses, since data on tocolytics or antibiotics were missing.
The ACS delivery interval varies and the proportion of optimally timed ACS (>24 h and ≤7 days before delivery) is generally poor (11) (12) (13) 17) . Previous studies have confirmed that women with PPROM have a longer ACS delivery interval compared with women with other obsteric indications (12) . The prediction of preterm delivery remains a clinical challenge and "treat all" strategies (18) could be exposing preterm neonates to unnecessary harm, as recently raised by Ridout et al. (19) . The lack of benefit and potential harm when the ACS birth interval exceeds seven days was recently highlighted (19, 20) and several studies have analyzed whether inappropriate use and timing of ACS could have an adverse effect on neonatal outcomes (15, 21) . The EPICE study confirmed that the benefits from ACS are temporary and are not likely to exceed seven days (4) . The ACT trial unexpectedly reported an increase in neonatal mortality after the implementation of ACS in low-and middle-income countries (22) .
Since the likelihood of delivery within the optimal window may not improve, the use of an additional dose of ACS (rescue dose) has been questioned (11) . A meta-analysis showed a beneficial effect of rescue ACS by reducing the risk of RDS and the neonatal composite outcome (23) . In this study, <40% of the women eligible according to the local protocols were treated with rescue ACS.
The present study and recent findings by Norberg et al. (16) suggest a change in clinical practice towards offering ACS to those most likely to deliver within seven days. The significance of the clinical scenario should be considered when deciding upon ACS administration. New strategies using fetal fibronectin and prediction algorithms have been suggested as a tool for clinicians to optimize the timing of ACS (24) . We suggest a change of practice from the standard "treat all" policy to expectant management for women with PPROM or mild vaginal bleeding in the absence of uterine activity or signs of infection; this could be evaluated in a prospective clinical study. 
Conclusion
Optimal timing of ACS treatment varied significantly based on the clinical indication. Women treated with ACS for PPROM and vaginal bleeding were more likely to have a less optimal ACS delivery interval of more than seven days. An ACS delivery interval more than seven days was associated with an increased risk of neonatal respiratory morbidity and a prolonged stay in the NICU. An improved timing of ACS might result in improved neonatal outcome.
